Researcher
Agnieszka Wozniak
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Jul 2006 → 30 Sep 2022
Projects
1 - 9 of 9
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Chicken chorioallantoic membrane (CAM) model as a research tool complementary to patient-derived xenografts (PDX) for preclinical drug testing in sarcomas.From1 Oct 2022 → TodayFunding: BOF - projects
- Preclinical evaluation of innovative cytotoxic drugs for the treatment of soft tissue sarcomaFrom28 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the biology of translocation-related sarcomas and impact on the research for new therapy options.From1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- CYTOTOXIC THERAPY REVISED: EXPLORATION OF INNOVATIVE (PRO)DRUGS IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMAFrom1 Sep 2018 → 25 Oct 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of soft tissue sarcoma and the potential clinical applicationsFrom26 Sep 2017 → 25 Feb 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical outcome, Pathological results and immunohistochemical findings of rare subtypes of soft tissue sarcomasFrom10 Aug 2015 → 30 Sep 2017Funding: Nonprofit institution or equivalents
- Establishment of new research models and in vivo efficacy testing of novel treatment strategies for resistant gastrointestinal stromal tumorsFrom1 Aug 2014 → 19 May 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting soft tissue sarcoma with smart molecules - exploring cytotoxic prodrugs and target-specific inhibitors in patient-derived xenograftsFrom1 Aug 2013 → 30 Nov 2017Funding: Nonprofit institution or equivalents
Publications
11 - 20 of 107
- Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets(2022)
Authors: Huiwen Che, Tatjana Jatsenko, Liesbeth Lenaerts, Nathalie Brison, Kris Van Den Bogaert, Ruben Heremans, Agnieszka Wozniak, Christophe Dooms, Els Wauters, Sigrid Hatse, et al.
Pages: 1164 - 1176 - Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma(2022)
Authors: Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
- Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma(2022)
Authors: Britt Van Renterghem, Agnieszka Wozniak, Raf Sciot, Patrick Schöffski
- Anti-tumor effects of the novel KIT mutant inhibitor M4205 in patient-derived gastrointestinal stromal tumor (GIST) xenograft models(2022)
Authors: Luna De Sutter, Agnieszka Wozniak, Lore De Cock, Raf Sciot
- In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor(2022)
Authors: Patrick Schöffski, Agnieszka Wozniak
- Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial(2022)
Authors: Elodie Modave, Bram Boeckx, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
- PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index(2022)
Authors: Britt Van Renterghem, Peter Pokreisz, Agnieszka Wozniak, Max Mazzone, Patrick Schöffski
Pages: 568 - 581 - Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma(2022)
Authors: Britt Van Renterghem, Agnieszka Wozniak, Raf Sciot, Patrick Schöffski
- Molecular characterization of soft tissue sarcoma and the potential clinical applications(2022)
Authors: Jerry Lee, Patrick Schöffski, Agnieszka Wozniak
- Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib(2021)
Authors: Jerry Lee, Patrick Schöffski, Elodie Modave, Bram Boeckx, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak
Pages: 6737 - 6748